Jiashili Group Ltd
HKEX:1285
Jiashili Group Ltd
HKEX:1285
Price:
1.15
HKD
1.77%
Market Closed
Market Cap:
HK$477.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Jiashili Group Ltd
HKEX:1285
|
CN |
|
T
|
Theriva Biologics Inc
AMEX:TOVX
|
US |
|
Xiaomi Corp
HKEX:1810
|
CN |
|
Meggitt PLC
LSE:MGGT
|
UK |
|
B
|
Bajaj Housing Finance Ltd
NSE:BAJAJHFL
|
IN |
|
Raymond James Financial Inc
NYSE:RJF
|
US |
|
S
|
Sino Biopharmaceutical Ltd
OTC:SBHMY
|
HK |
|
R
|
Rumere Co Ltd
SZSE:301088
|
CN |
Income Statement
Earnings Waterfall
Jiashili Group Ltd
Jiashili Group Ltd
Income Statement
Jiashili Group Ltd
Jiashili Group Ltd
Currency: CNY
| Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
12
|
17
|
23
|
20
|
20
|
22
|
21
|
31
|
37
|
31
|
30
|
29
|
31
|
29
|
0
|
0
|
|
| Revenue |
1 293
N/A
|
1 449
+12%
|
1 566
+8%
|
1 593
+2%
|
1 583
-1%
|
1 519
-4%
|
1 485
-2%
|
1 597
+8%
|
1 672
+5%
|
1 764
+6%
|
1 763
0%
|
1 686
-4%
|
1 707
+1%
|
1 803
+6%
|
1 747
-3%
|
1 627
-7%
|
|
| Gross Profit | |||||||||||||||||
| Cost of Revenue |
(886)
|
(987)
|
(1 051)
|
(1 054)
|
(1 044)
|
(1 008)
|
(1 006)
|
(1 138)
|
(1 249)
|
(1 302)
|
(1 245)
|
(1 185)
|
(1 233)
|
(1 292)
|
(1 241)
|
(1 145)
|
|
| Gross Profit |
407
N/A
|
462
+14%
|
515
+11%
|
539
+5%
|
539
0%
|
511
-5%
|
480
-6%
|
459
-4%
|
423
-8%
|
462
+9%
|
518
+12%
|
501
-3%
|
474
-5%
|
511
+8%
|
506
-1%
|
482
-5%
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(274)
|
(335)
|
(337)
|
(396)
|
(423)
|
(344)
|
(274)
|
(311)
|
(395)
|
(381)
|
(370)
|
(401)
|
(382)
|
(404)
|
(413)
|
(322)
|
|
| Selling, General & Administrative |
(248)
|
(306)
|
(308)
|
(365)
|
(380)
|
(300)
|
(226)
|
(255)
|
(342)
|
(336)
|
(328)
|
(362)
|
(342)
|
(389)
|
(396)
|
(291)
|
|
| Research & Development |
(40)
|
(44)
|
(49)
|
(52)
|
(54)
|
(60)
|
(64)
|
(65)
|
(65)
|
(59)
|
(54)
|
(57)
|
(58)
|
(53)
|
(51)
|
0
|
|
| Other Operating Expenses |
14
|
15
|
21
|
21
|
11
|
16
|
16
|
9
|
12
|
14
|
12
|
18
|
18
|
39
|
34
|
(31)
|
|
| Operating Income |
133
N/A
|
127
-5%
|
178
+40%
|
143
-20%
|
115
-19%
|
167
+45%
|
206
+23%
|
147
-28%
|
27
-82%
|
81
+197%
|
148
+83%
|
101
-32%
|
92
-9%
|
106
+16%
|
93
-13%
|
160
+71%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
(1)
|
(16)
|
(21)
|
(4)
|
5
|
2
|
(5)
|
(8)
|
(4)
|
(3)
|
(6)
|
(23)
|
(25)
|
(17)
|
(15)
|
(22)
|
|
| Non-Reccuring Items |
(0)
|
(0)
|
(0)
|
8
|
8
|
0
|
(0)
|
0
|
0
|
(0)
|
(0)
|
13
|
11
|
(12)
|
(11)
|
(0)
|
|
| Pre-Tax Income |
132
N/A
|
111
-16%
|
156
+41%
|
147
-6%
|
129
-13%
|
169
+32%
|
201
+19%
|
140
-31%
|
23
-84%
|
77
+237%
|
142
+84%
|
90
-37%
|
79
-13%
|
77
-2%
|
67
-13%
|
137
+104%
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
(24)
|
(25)
|
(32)
|
(39)
|
(35)
|
(24)
|
(21)
|
(32)
|
(16)
|
(15)
|
(33)
|
(29)
|
(26)
|
(29)
|
(26)
|
(31)
|
|
| Income from Continuing Operations |
108
|
86
|
125
|
109
|
94
|
145
|
180
|
108
|
7
|
62
|
109
|
61
|
53
|
48
|
41
|
107
|
|
| Income to Minority Interest |
0
|
0
|
0
|
1
|
0
|
(3)
|
1
|
7
|
6
|
2
|
6
|
3
|
4
|
6
|
3
|
2
|
|
| Net Income (Common) |
108
N/A
|
86
-20%
|
125
+44%
|
110
-12%
|
94
-14%
|
143
+52%
|
181
+27%
|
115
-36%
|
13
-89%
|
65
+415%
|
92
+42%
|
64
-31%
|
57
-11%
|
54
-4%
|
45
-18%
|
109
+143%
|
|
| EPS (Diluted) |
0.26
N/A
|
0.21
-19%
|
0.3
+43%
|
0.26
-13%
|
0.23
-12%
|
0.34
+48%
|
0.44
+29%
|
0.28
-36%
|
0.03
-89%
|
0.16
+433%
|
0.22
+38%
|
0.15
-32%
|
0.14
-7%
|
0.13
-7%
|
0.11
-15%
|
0.26
+136%
|
|
Switch to:
Switch to:
See Also
Discover More
